1. Signaling Pathways
  2. Protein Tyrosine Kinase/RTK
  3. SHP2

SHP2

Src homology phosphatase 2; PTPN11

Src-homology-2-containing protein tyrosine phosphatase 2 (SHP2), encoded by the PTPN11 gene, is a 593 amino acid classical non-receptor protein tyrosine phosphatase (PTP). SHP2 is involved in diverse signalling pathways such as RAS-MAPK, PI3K-AKT, JAK-STAT and PD-1/PD-L1. Besides, SHP2 negatively regulates the activation of recombinant NLRP3 (NLR family, pyrin domain containing protein 3) inflammasome via mitochondrial homeostasis. SHP2 has been regarded as an extremely attractive target for human diseases therapies, particular in cancer.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-155273
    SHP2-IN-17
    SHP2-IN-17 (compound 192) is a SHP2 inhibitor with an IC50 value of 2 nM. SHP2-IN-17 can be used for glioblastoma research.
    SHP2-IN-17
  • HY-162233
    SHP2-IN-25
    Inhibitor
    SHP2-IN-25 (Compound 6) is a SHP2 allosteric inhibitor, with an IC50 of 225 nM. SHP2-IN-25 can be used for the research of cancer.
    SHP2-IN-25
  • HY-172916
    LC-SF-14
    Inhibitor
    LC-SF-14 is a selective dual inhibitor of SHP2 and FGFR (IC50 values are 71.6 and 8.9 nM, respectively). LC-SF-14 inhibits FGFR2-FRS2α-SHP2-MAPK signaling and ERK phosphorylation. LC-SF-14 inhibits the proliferation of KATOIII cancer cells (IC50: 9.2 nM). LC-SF-14 has antitumor activity in the SNU-16 xenograft mouse model. LC-SF-14 can be used in FGFR2-driven gastric cancer research.
    LC-SF-14
  • HY-173573
    TK-684
    Inhibitor
    TK-684 is a potent and selective allosteric SHP2 inhibitor with IC50 values of 2.1, >1000 nM for SHP2WT, SHP22PTP, respectively. TK-684 inhibits cell proliferation and induces apoptosis. TK-684 decreases the protein expression of p-AKT, p-ERK.
    TK-684
  • HY-172454
    SHP2-IN-36
    Inhibitor
    SHP2-IN-36 (Compound B8) is an allosteric inhibitor of SHP2, with an IC50 value of 9.0 nM. In addition, its IC50 for p-ERK is 40 nM. SHP2-IN-36 also exhibited significant antitumor activity in the KYSE520 xenograft mouse model. SHP2-IN-36 can be used for research in the field of anti-tumor .
    SHP2-IN-36
  • HY-155275
    SHP2-IN-19
    SHP2-IN-19 (compound 183) is a SHP2 inhibitor with an IC50 value of 3 nM. SHP2-IN-19 can be used for glioblastoma research.
    SHP2-IN-19
  • HY-125260
    SHP844
    Inhibitor
    SHP844 is a SHP2 inhibitor with the IC50 of 18.9 µM. SHP2 is a protein tyrosine phosphatase (PTP) that regulates tyrosine phosphorylation levels and is involved in cell proliferation, differentiation and survival.
    SHP844
  • HY-N10079
    Suchilactone
    Inhibitor
    Suchilactone (Jatrophan) is a lignan extracted from Monsonia angustifolia E.Mey. Suchilactone binds to SHP2 and inhibits SHP2 activation, thereby inhibiting ERK-mediated cell proliferation. Suchilactone can be ued in acute myeloid leukaemia (AML).
    Suchilactone
  • HY-155277
    SHP2-IN-21
    SHP2-IN-21 (compound 208) is a SHP2 inhibitor with an IC50 value of 3 nM. SHP2-IN-21 can be used for glioblastoma research.
    SHP2-IN-21
  • HY-155274
    SHP2-IN-18
    SHP2-IN-18 (compound 183) is a SHP2 inhibitor with an IC50 value of 3 nM. SHP2-IN-18 can be used for glioblastoma research.
    SHP2-IN-18
  • HY-162755
    SHP2-IN-30
    Inhibitor
    SHP2-IN-30 (compound 14i) is an allosteric SHP2 inhibitor with an IC50 of 104 nM. SHP2-IN-30 shows low inhibitory effect on SHP2-PTP. SHP2-IN-30 induces cell apoptosis and arrests the cell cycle at the G0/G1 phase.
    SHP2-IN-30
  • HY-158762
    TK-642
    Inhibitor
    TK-642 is a highly active, selective, orally activity SHP2 inhibitor based on pyrazole and pyrazine (IC50=2.7 nmol/L). TK-642 can effectively inhibit the proliferation of esophageal carcinoma cells and induce cell apoptosis. TK-642 can be used in the study of esophageal cancer.
    TK-642
  • HY-P3444A
    CD31 TFA
    CD31 (PECAM-1) TFA is platelet endothelial cell adhesion molecule-1, serves as the endothelial cell-specific receptor of clostridium perfringens b-Toxin (CPB). CD31 TFA is also an ER-MP12 antigen, acts as a linker between mechanical stress, metabolism and inflammation. CD31 TFA peptide is able to sustain phosphorylation of the CD31 ITIM686 and of SHP2 and to inhibit TCR-induced T-cell activation-.
    CD31 TFA
  • HY-159489
    SDUY038
    Inhibitor
    SDUY038 is a SHP2 allosteric inhibitor, with an IC50 of 1.2 μM and KD of 0.29 μM, respectively. SDUY038 exhibits pan-antitumor activity (IC50 = 7-24 μM) by suppressing pERK expression. SDUY038 exhibits t1/2 of 3.95 h by oral administration.
    SDUY038
  • HY-173571
    TK-685
    Inhibitor
    TK-685 is an orally active, selective, and allosteric SHP2 inhibitor with an IC50 of 2.1 nM. TK-685 inhibits esophageal cancer cell proliferation and induced apoptosis by targeting SHP2-mediated AKT and ERK signaling pathways.
    TK-685
  • HY-152208
    BPDA2
    Inhibitor
    BPDA2 is a highly selective and competitive active site SHP2 inhibitor with IC50s of 92.0 nM, 33.39 μM, 40.71 μM for SHP2, SHP1, SHP1B, respectively. DBDA2 downregulates mitogenic and cell survival signaling and RTK expression. BPDA2 suppresses SHP2 mediated signaling and breast cancer cell phenotypes.
    BPDA2
  • HY-141524
    RMC-3943
    Inhibitor
    RMC-3943 is an allosteric SHP2 inhibitor (inhibition of full-length SHP2 in biochemical assay, IC50 = 2.19 nM).
    RMC-3943
  • HY-125259
    SHP504
    Inhibitor
    SHP504 is a SHP2 phosphatase inhibitor, with an IC50 of 21 μM for SHP21–525.
    SHP504
  • HY-157535
    SHP2-IN-24
    Inhibitor
    SHP2-IN-24 (compound 111675) is a potent SHP2 inhibitor with an IC50 value of 0.878 µM and a Ki value of 0.118 µM.
    SHP2-IN-24
  • HY-120901
    II-B08
    Inhibitor
    II-B08 is a reversible and noncompetitive SHP2 inhibitor (IC50: 5.5 μM, 15.7, 14.3 μM for SHP2, SHP1, PTP1B). II-B08 can be used for cancer research.
    II-B08
Cat. No. Product Name / Synonyms Application Reactivity